搜索
 > 【B7-2】重组蛋白信息

B7-2信息

英文名称:Cluster of Differentiation 86
中文名称:分化群86
靶点别称:T-lymphocyte activation antigen CD86,FUN-1,CTLA-4 counter-receptor B7.2,CD86,B70,BU63,CD_antigen=CD86,Activation B7-2 antigen,CD28LG2
上市药物数量:2
临床药物数量:9
最高研发阶段:批准上市

B7-2 分子别名

CD86,B7-2,B70,CD28LG2,LAB72,MGC34413

B7-2 分子背景

Cluster of Differentiation 86 (CD86) is also known as B-lymphocyte activation antigen B7-2, is a type I membrane protein that is a member of the immunoglobulin superfamily, and is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B72 is expressed at low levels on monocytes and can be upregulated through interferon γ. CD86 is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD86 works in tandem with CD80 to prime T cells. Recent study has revealed that B7-2 promotes the generation of a mature APC repertoire and promotes APC function and survival. Furthermore, the B7 proteins are also involved in innate immune responses by activating NF-κB-signaling pathway in macrophages. CD86 thus is regarded as a promising candidate for immune therapy. CD86+ macrophages in Hodgkin lymphoma patients are an independent marker for potential nonresponse to firstline-therapy.

B7-2 参考文献

B7-2上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Belatacept BMS-224818; LEA29Y; L104EA29YIg; LEA-029 批准上市 百时美施贵宝 NULOJIX fda 器官移植排斥 BRISTOL MYERS SQUIBB 2011-06-15 器官移植排斥, 肾移植排斥反应 详情
Abatacept BMS-188667; ONO-4164; BMS-188667SC; ONO-4164SC,MS188667; ONO4164; BMS188667SC; ONO4164SC 批准上市 百时美施贵宝, 小野制药 ORENCIA fda 类风湿性关节炎, 幼年型类风湿性关节炎 BRISTOL MYERS SQUIBB 2005-12-23 幼年特发性关节炎, 类风湿性关节炎, 幼年型类风湿性关节炎 详情

B7-2临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
KN-019 KN-019,KN019; KN 019 临床一期 苏州康宁杰瑞生物科技 肾移植排斥反应
Immunogene therapy (Briana Bio-Tech) 临床一期 University of Alberta, Briana Bio-tech Inc 神经胶质瘤, 黑色素瘤
Abatacept biosimilar (Momenta Pharmaceuticals) M-834 临床一期 Momenta, 迈兰制药 自身免疫疾病, 免疫炎症 详情
Attenuated viral vector immunogene-based therapy and vaccine (Radient Pharmaceuticals) 临床一期 Radient, Jaiva Technologies 癌症
Abatacept biosimilar (Hanwha Biologics) 临床阶段不明 Hanwha Biologics 关节炎
Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) Z-CTLs 临床一期 湖南昭泰涌仁医疗创新有限公司 非小细胞肺癌
Abatacept biosimilar (Shanghai CP Guojian Pharmaceutical) BLA 申请 三生国健药业(上海) 类风湿性关节炎
ASP-2408 ASP-2408 临床一期 Maxygen, 安斯泰来 类风湿性关节炎 详情
CTLA-4/FasL fusion protein (KAHR Medical) KAHR-102 临床申请 KAHR Medical 淋巴瘤 详情

消息提示

请输入您的联系方式,再点击提交!

确定